Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Affinium Pharmaceuticals (Austin, TX) a clinical-stage specialty pharmaceutical company focused on small molecule antibiotics targeting staph and MRSA infections, closed a $15M Series B financing. Participants include SV Life Sciences, Genesis Capital Partners, Forward Ventures and Ontario Emerging Technologies Fund. Thanx for your patience as we catch-up.

Novophage (Boston, MA) a development-stage synthetic biology company focused on antimicrobial biofilms, closed a $5.7M Series A financing. Participants include Flybridge Capital Partners, Chevron Technology Ventures, Founder Collective and The Kraft Group.

Tyrx (Monmouth Junction, NJ) a commercial-stage drug:device combo company focused on a dissolving antibacterial biocompatible mesh envelope to house implanted devices such as pacemakers and defibrillators, closed a $16M Series C financing. Participants include HLM Venture Partners, Clarus Ventures and Pappas Ventures.

MerLion Pharmaceuticals (Singapore) a clinical-stage small molecule company focused on antibacterials for the treatment of urinary tract infections, closed a $7 Series C financing. Participants include Aravis Venture Associates, Aurelia Private Equity, Bio*One Capital and Heidelberg Capital.

Great Lakes Pharmaceuticals (Cleveland, OH) a clinical-stage drug:device company focused on catheter-related bloodstream infection, closed a $3.1M Series B financing. Participants include Charter Life Sciences, Early Stage Partners, Ohio Tech Angels and North Coast Angel Fund.

Tetraphase Pharmaceuticals (Watertown, MA) a clinical-stage biopharmaceutical company focused on broad spectrum antibiotics for the treatment of gram negative pathogens, unrinary tract infections and community acquired bacterial pneumonia, closed a $45M Series C financing. Participants include Excel Venture Management, CMEA Capital, Fidelity Biosciences, Flagship Ventures, Mediphase Venture Partners and Skyline Ventures.

AiCuris (Germany) a clinical-stage biopharmaceutical company focused on resistance breaking antiviral and antibacterial therapeutics targeting Human Cytomegalovirus, Herpes simplex, HIV, Hepatitis B and C and multi-resistant bacteria, closed a $74.8M Series B financing. Participants include Santo Holding and Bayer Healthcare.

Achaogen (San Francisco, CA) a clinical-stage a biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat life-threatening, multi-drug resistant bacterial infections, closed a $56M Series C financing. Participants include Frazier Healthcare Ventures, Alta Partners, 5 AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates, Versant Ventures and Wellcome Trust.

Aquapharm Biodiscovery (United Kingdom) a preclinical-stage discovery and development company focused on a marine based platform for the identification antimicrobial compounds, closed a $6.4M Series C financing. Participants include Aescap Venture, Tate & Lyle Ventures, Highlands and Islands Enterprise and NESTA.

Novacta Biosystems (United Kingdom) a pre-clinical stage biopharmaceutical company developing anti-invectives against C. difficile, closed a $21.6M Series B financing. Participants include Celtic Pharma.

Cempra Pharmaceuticals (Chapel Hill, NC) a clinical-stage company developing antibiotics for difficult-to-treat and drug-resistant infections, closed a $46M Series C financing. Participants include Quaker BioVentures, Devon Park Bioventures, Aisling Capital, Intersouth Partners, Teachers’ Private Capital and I. Wistar Morris III.

GlycoVaxyn (Switzerland) a preclinical-stage company developing vaccines focused on bacterial caused disease, closed a $22M Series B financing. Participants include Edmond de Rothschild Investment Partners, Index Ventures and Sofinnova Partners.

Kenta Biotech (Switzerland) clinical-stage developer of antibacterial and antiviral antibodies targeting Pseudomonas aeruginosa caused nosocomial pneumonia closed a $10M Series B financing. Participants in this round have not been identified.

« Previous Entries  Next Page »

to top of page...